文献速递湿疹皮炎与荨麻疹

TREAT登记工作组:度普利尤单抗及其他系统治疗特应性皮炎安全性研究方案

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
PubMed 文献 · Br J Dermatol · 2019-11-20

TREAT登记工作组发布一项嵌入登记的国际前瞻性观察性队列研究方案,纳入开始使用度普利尤单抗或其他系统免疫调节剂治疗的中重度特应性皮炎成人和儿童患者,主要终点为恶性肿瘤(除外非黑色素瘤皮肤癌)发生率,次要终点包括其他严重不良事件及特殊关注不良事件如眼部疾病和嗜酸性粒细胞增多。该方案旨在常规临床实践中评估长期安全性,并可推广至其他新型系统免疫调节治疗。

要点

  • 比较度普利尤单抗与其他系统免疫调节剂在特应性皮炎中的长期安全性。
  • 主要终点为恶性肿瘤(除外非黑色素瘤皮肤癌)发生率。
  • 次要终点包括严重不良事件及眼部疾病、嗜酸性粒细胞增多等特殊关注事件。

核心结论

  • 该方案提出通过多国登记网络开展国际前瞻性观察性队列研究,比较度普利尤单抗与其他系统免疫调节剂在特应性皮炎患者中的长期安全性。
  • 研究结果可为监管机构、支付方、制药公司和临床医生提供常规临床实践中的安全性证据。

研究设计与样本

  • 研究设计为嵌入登记的国际前瞻性观察性队列研究。
  • 纳入开始使用度普利尤单抗或其他系统免疫调节剂治疗的中重度特应性皮炎成人和儿童患者。

关键数值与推荐

  • 主要终点为恶性肿瘤(除外非黑色素瘤皮肤癌)发生率,比较治疗组间差异。
  • 次要终点包括其他严重不良事件和特殊关注不良事件,如眼部疾病和嗜酸性粒细胞增多。

临床怎么用

  • 该方案采用跨多国登记的标准化方法学,可用于其他新型系统免疫调节治疗的长期安全性研究。
  • 研究在常规临床实践环境中开展,可补充随机对照试验未覆盖的长期安全性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A long-term prospective observational safety study is essential to characterize fully the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data using a predefined core dataset. OBJECTIVES: To present a protocol for a safety study comparing dupilumab with other systemic immunomodulating therapies in children and adults with moderate-to-severe atopic eczema, to assess the long-term safety risk of these therapies in a routine clinical care setting. METHODS: We describe a registry-embedded international observational prospective cohort study. Adult and paediatric patients who start treatment with dupilumab or another systemic immunomodulating agent for their atopic eczema will be included. The primary end point is the incidence of malignancies (excluding nonmelanoma skin cancer) compared between the treatment groups. Secondary end points include other serious adverse events and adverse events of special interest, such as eye disorders and eosinophilia. CONCLUSIONS: This protocol delineates a safety study for dupilumab in adult and paediatric patients with atopic eczema, using a standardized methodological approach across several national registries. The protocol could also be used for other novel systemic immunomodulating therapies, and could provide licensing and reimbursement authorities, pharmaceutical companies and clinicians with safety evidence from a routine clinical care setting. What's already known about this topic? There is a need for long-term data on the safety of systemic immunomodulating therapies in patients with atopic eczema. Regulatory bodies, such as the European Medicines Agency, increasingly stipulate the collection of such data as part of the licensing agreement for new treatments, to assess the new agent's long-term safety profile against established therapies. Large numbers of patients with a long duration of follow-up are necessary in order to detect rare events like malignancies. What does this study add? The TREAT Registry Taskforce offers a platform to conduct such research with a network of multiple national atopic eczema research registries. We present a protocol for an investigator-initiated multicentre safety study comparing dupilumab with other systemic immunomodulating therapies in adults and subsequently adolescents and children with moderate-to-severe atopic eczema. This protocol can be used as a framework for similar studies for other novel systemic immunomodulating therapies across both adult and paediatric populations.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Bosma AL, Spuls PI, Garcia-Doval I, et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. Br J Dermatol. 2019. PMID: 31444799. doi:10.1111/bjd.18452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。